Sugi Predict

Sugi Predict / Compounds / SCHEMBL1724568

SCHEMBL1724568

SCHEMBL1724568

CC(=O)Oc1ccc(-c2coc3cc(OC(C)=O)ccc3c2=O)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.85
▸ RAB9A P51151 8/20 0.85
▸ NPC1 O15118 8/20 0.85
▸ SMN1; SMN2 Q16637 8/20 0.85
▸ ALDH1A1 P00352 6/20 0.85
▸ KDM4E B2RXH2 4/20 0.85
▸ ALDH2 P05091 5/20 0.67
▸ MAOA P21397 4/20 0.67
▸ MAOB P27338 4/20 0.67
▸ XDH P47989 1/20 0.64
▸ MEN1 O00255 5/20 0.64
▸ KMT2A Q03164 5/20 0.64
▸ MAPK1 P28482 4/20 0.64
▸ TSHR P16473 2/20 0.64
▸ LMNA P02545 2/20 0.64
▸ POLB P06746 3/20 0.63
▸ HDAC6 Q9UBN7 2/20 0.63
▸ GAA P10253 1/20 0.63
▸ PTGS1 P23219 1/20 0.63
▸ SLC6A2 P23975 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10338453 0.94 KDM4E (0.80) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL2069145 0.94 RAB9A (0.80) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12238020 0.94 RAB9A (0.80) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL4434901 0.92 RAB9A (0.78) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL12289030 0.92 RAB9A (0.78) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL2070406 0.92 NPC1 (1.00) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL2604722 0.91 ALDH1A1 (0.72) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL2069266 0.88 MAPT (0.84) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL19410274 0.87 ALDH2 (0.68) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL1038112 0.87 MAPT (0.78) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143588-A1 Production of isoflavone derivatives NOVOGEN RESEARCH PTY LTD. 2005-06-30 — — US claimed
EP-3191464-B1 SYNTHESIS OF ISOFLAVANES AND INTERMEDIATES THEREOF SYSTEM BIOLOGIE AG (CH) 2019-11-06 — — EP disclosed
US-10030003-B2 Synthesis of isoflavanes and intermediates thereof SYSTEM BIOLOGIE AG (CH) 2018-07-24 — — US disclosed
US-10030003-B2 Synthesis of isoflavanes and intermediates thereof SYSTEM BIOLOGIE AG (CH) 2018-07-24 — — US disclosed
US-20170283389-A1 Synthesis of Isoflavanes and Intermediates Thereof SYSTEM BIOLOGIE AG (CH) 2017-10-05 — — US disclosed
US-20170283389-A1 Synthesis of Isoflavanes and Intermediates Thereof SYSTEM BIOLOGIE AG (CH) 2017-10-05 — — US disclosed
US-20160136129-A1 CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY NOVOGEN RESEARCH PTY LTD (AU) 2016-05-19 — — US disclosed
US-9198895-B2 Chroman derivatives, medicaments and use in therapy MEI PHARMA, INC. (US) 2015-12-01 — — US disclosed
US-20150240275-A1 ENZYME ASSOCIATED WITH EQUOL SYNTHESIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-08-27 — — US disclosed
US-20150238458-A1 CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY NOVOGEN RESEARCH PTY LTD (AU) 2015-08-27 — — US disclosed
EP-2228441-A1 ENZYME INVOLVED IN SYNTHESIS OF EQUOL Otsuka Pharmaceutical Co., Ltd. (JP) 2010-09-15 — — EP disclosed
US-7696363-B2 Preparation of flavonoid compounds YASOO HEALTH INC. (US) 2010-04-13 — — US disclosed
US-7696363-B2 Preparation of flavonoid compounds YASOO HEALTH INC. (US) 2010-04-13 — — US disclosed
US-20070149788-A1 Preparation of Flavonoid Compounds YASOO HEALTH, INC. 2007-06-28 — — US disclosed
US-20070149788-A1 Preparation of Flavonoid Compounds YASOO HEALTH, INC. 2007-06-28 — — US disclosed
US-20060217564-A1 Production of isoflavone derivatives NOVOGEN RESEARCH PTY LTD. 2006-09-28 — — US disclosed
US-20050143588-A1 Production of isoflavone derivatives NOVOGEN RESEARCH PTY LTD. 2005-06-30 — — US disclosed
EP-1153020-A4 PRODUCTION OF ISOFLAVONE DERIVATIVES NOVOGEN RES PTY LTD (AU) 2002-08-21 — — EP disclosed
EP-1153020-A1 PRODUCTION OF ISOFLAVONE DERIVATIVES Novogen Research Pty. Ltd. (AU) 2001-11-14 — — EP disclosed
WO-2000049009-A1 PRODUCTION OF ISOFLAVONE DERIVATIVES NOVOGEN RESEARCH PTY. LTD. (AU) 2000-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150238458-A1 CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY CDYL, XPA, TP53 MAPT 2679/4885RAB9A 3764/4885NPC1 1793/4885
US-20060217564-A1 Production of isoflavone derivatives CYP51A1, EGLN2, EGLN3 MAPT 3761/4885RAB9A 3050/4885NPC1 2144/4885
US-10030003-B2 Synthesis of isoflavanes and intermediates thereof CYP4B1, CYP51A1, CYP4A11 MAPT 4096/4885RAB9A 4077/4885NPC1 2315/4885
US-20170283389-A1 Synthesis of Isoflavanes and Intermediates Thereof CYP4B1, CYP51A1, CYP4A11 MAPT 4096/4885RAB9A 4077/4885NPC1 2315/4885
US-20050143588-A1 Production of isoflavone derivatives CYP51A1, EGLN2, EGLN3 MAPT 3761/4885RAB9A 3050/4885NPC1 2144/4885
US-20160136129-A1 CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY CDYL, XPA, TP53 MAPT 2679/4885RAB9A 3764/4885NPC1 1793/4885
US-20070149788-A1 Preparation of Flavonoid Compounds EGLN2, HPD, SDHA MAPT 2979/4885RAB9A 2082/4885NPC1 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.